Th e session on undue and disproportionate infl uences included three presentations that considered areas of profound importance for investigators involved with breast cancer research. Th e fi rst two presentations focused on areas that substantially impact the inter pretation of scientifi c research, peer review and the topic of statistical signifi cance. Clearly, both these topics have an importance that extends beyond breast cancer to all research. Th e third presentation considered whether randomized adjuvant therapy trials in early breast cancer were necessary for drug development, which is a topic of increasing importance given the increasing number of potentially valuable drugs that are in development and the corresponding increase in restrictions and limitations on funding available for the conduct of clinical research.
Peer review is considered the essential process by which judgments can be made regarding the quality of a manuscript, a grant proposal or other scholarly work. Despite acknowledgement of peer review as the cornerstone for making these judgments, there is widespread appreciation of the shortcomings and defi ciencies of this process. Using his vast background as editor of a major journal, Doctor Richard Smith [1] provided his views on classical peer review. He defi ned peer review and addressed its problems before asking whether it could be done better and has undue infl uence. In doing so, insights into the process of manuscript review that might be considered provocative and controversial were put forward. Th us, in defi ning peer review, Dr Smith indicated that there was no operational defi nition but that it was 'something to do with a third party reviewing manuscripts and grant proposals before a fi nal decision is made' Th ere are as many peer review systems as there are journals and grant giving bodies. Convention has it that peer review serves to select the best studies, improve what is published and detect errors and fraud. However, Th e Cochrane Collaboration [2, 3] suggests that ' At present, little empirical evidence is available to support the use of editorial peer review as a mechanism to ensure quality of biomedical research' and 'Th ere is little empirical evidence on the eff ects of grant giving peer review. No studies assessing the impact of peer review on the quality of funded research are presently available. ' Dr Smith also indicated that the peer review process was frequently slow, expensive, time consuming and based on chance. It often failed to detect errors, can be biased and abused, and has a disproportionate infl uence on what is published and funded. Because of these characteristics, peer review is often a fl awed process that subtracts rather than adds value. Dr Smith advocated scrapping prepublication review and instead concentrating on real post-publication peer review (that will happen anyway). Th e question of conducting open versus anonymous peer review was worthy of vigorous debate.
Professor Judith Bliss, Director of the Institute of Cancer Research Clinical Trials and Statistics Unit, provided a thoughtful and enlightening review of Pvalues in the context of clinical research, a subject at the center of interpretation of such trials. She asked that investigators should be able to distinguish between probability of observing a diff erence as large as that seen when there is no diff erence between treatments group (correct statistical application of P-values) and probability that there is no diff erence between treatment groups given the data observed (popular misconception of P-values). Th e origin for choosing 'P < 0.05' as a standard was traced back to Fisher in 1925 [4] , although he was himself prepared to be fl exible when attributing signifi cance and fortitude with regard to actual P-values. Researchers were urged to interpret P-values in the context of the observations used to derive them and thereby not fall into the trap of allowing P-values to impair understanding of research results [5] . Specifi c examples were considered of 'signifi cant but not substantial' and vice versa. Professor Bliss also addressed the important issue of 'clinical signifi cance' in the setting of 'statistical signifi cance' and provided valuable insights into statistical considerations that are important to the clinician who must make judgments regarding fi ndings reported in the literature. 
